磁性蛋白微球阿霉素的定性研究

Qualitative study of adriamycin magnetic albumin microspheres

目的 对采用改良方法自行制备抗肿瘤药物磁性白蛋白微球阿霉素进行定性研究和评价。方法 采用改良方法自行制备抗肿瘤药物磁性白蛋白微球阿霉素 ,并经细胞图像分析仪二值化处理 ,优选出符合静脉用药的最佳磁微球 (0 .91± 0 .3 3 ) μm ,并以小鼠和豚鼠为实验对象 ,对该复合物进行定性分析 ,观察 (长达 6周 )该复合药物的急性、亚急性等毒性实验 ,并作相应的病理学检查。同时 ,测定其LD50 值。结果 该复合药物对实验动物的组织细胞并没有毒性损伤 ,也没有在体内蓄积。其LD50 值为 2 3 .3mg/kg体重 ,高于单纯阿霉素静脉给药的LD50 值 (2 0 .0mg/kg体重 )。结论 该复合物毒性很小 ,具有可靠的安全性 ,并优于单纯阿霉素。

Objective To qualitatively assess the magnetic albumin microspheres carrying adriamycin.Methods Magnetic albumin microspheres carrying adriamycin were synthesized by a modified method and analyzed physically by a cytological image processing computer to be satisfactorily used intravenously (0.91±0.33)?μm.Some toxicological tests such as acute toxic test,subacute toxic test and anaphylactic test were done on mice and guinea pigs.Results The experimental findings did not show macroscopically and microscopically direct cytotoxic injuries to the animal organs or to the tissue cells within 6 week observations.The value of the drug's LD 50 (23.3?mg/kg) was calculated to be higher than that of the single used adriamycin (20.0?mg/kg),which meant the compound was less toxic than the adriamycin and quite safe in its therapeutic dosage.Conclusion This compound drug was not toxic and quite safe in its use.